NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today
August 17 2021 - 2:32PM
Business Wire
NanoVibronix, Inc.,
(NASDAQ: NAOV) (the “Company”), a healthcare device company that
produces the UroShield® and PainShield® Surface Acoustic Wave (SAW)
Portable Ultrasonic Therapeutic Devices, announced that the
Company’s Annual Meeting of Stockholders was held today virtually
and broadcast live at
www.virtualshareholdermeeting.com/NAOV2021.
All of the resolutions submitted for stockholder approval were
adopted, including:
- Election of the six director nominees
- Approval of the amendment to the company’s amended and restated
certificate of incorporation to increase the number of authorized
shares of common stock.
- Ratification of appointment of Marcum LLP as the company’s
independent registered public accounting firm
- Approval, on an advisory basis, of the compensation paid to the
company’s named executive officers
- Approval, on an advisory basis, of the frequency of future
advisory votes on the compensation paid to the company’s named
executive officers
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company
headquartered in Elmsford, New York, with research and development
in Nesher, Israel, focused on developing medical devices utilizing
its patented low intensity surface acoustic wave (SAW) technology.
The proprietary technology allows for the creation of low-frequency
ultrasound waves that can be utilized for a variety of medical
applications, including for disruption of biofilms and bacterial
colonization, as well as for pain relief. The devices can be
administered at home without the assistance of medical
professionals. The Company’s primary products include PainShield®
and UroShield®, which are portable devices suitable for
administration at home without assistance of medical professionals.
Additional information about NanoVibronix is available at:
www.nanovibronix.com.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and
uncertainties associated with: (i) our history of losses and
expectation of continued losses, (ii) the geographic, social and
economic impact of COVID-19 on the Company’s business operations,
(iii) our ability to raise funding for, and the timing of, clinical
studies and eventual U.S. Food and Drug Administration approval of
our product candidates, (iv) regulatory actions that could
adversely affect the price of or demand for our approved products,
(v) market acceptance of existing and new products, (vi) favorable
or unfavorable decisions about our products from government
regulators, insurance companies or other third-party payers, (vii)
risks of product liability claims and the availability of
insurance, (viii) our ability to successfully develop and
commercialize our products, (ix) our ability to generate internal
growth, (x) risks related to computer system failures and
cyber-attacks, (xi) our ability to obtain regulatory approval in
foreign jurisdictions, (xii) uncertainty regarding the success of
our clinical trials for our products in development, (xiii) risks
related to our operations in Israel, including political, economic
and military instability, (xiv) the price of our securities is
volatile with limited trading volume, (xv) our ability to comply
with the continued listing requirements of the NASDAQ capital
market, (xvi) our ability to maintain effective internal control
over financial reporting and to remedy identified material
weaknesses, (xvii) we are a “smaller reporting company” and have
reduced disclosure obligations that may make our stock less
attractive to investors, (xviii) our intellectual property
portfolio and our ability to protect our intellectual property
rights, (xix) our ability to recruit and retain qualified
regulatory and research and development personnel, (xx) unforeseen
changes in healthcare reimbursement for any of our approved
products, (xxi) the adoption of health policy changes and health
care reform, (xxii) lack of financial resources to adequately
support our operations, (xxiii) difficulties in maintaining
commercial scale manufacturing capacity and capability, (xxiv) our
ability to generate internal growth, (xxv) changes in our
relationship with key collaborators, (xxvi) changes in the market
valuation or earnings of our competitors or companies viewed as
similar to us, (xxvii) our failure to comply with regulatory
guidelines, (xxviii) uncertainty in industry demand and patient
wellness behavior, (xxix) general economic conditions and market
conditions in the medical device industry, (xxx) risks related to
our operations in Israel, (xxxi) future sales of large blocks of
our common stock, which may adversely impact our stock price, and
(xxxii) depth of the trading market in our common stock. More
detailed information about the Company and the risk factors that
may affect the realization of forward-looking statements is set
forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s web site at: http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events, or
otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210817005826/en/
Investor Contacts: Brett Maas, Managing Principal, Hayden IR,
LLC brett@haydenir.com (646) 536-7331
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From May 2024 to Jun 2024
NanoVibronix (NASDAQ:NAOV)
Historical Stock Chart
From Jun 2023 to Jun 2024